Parallax Volatility Advisers
GYRE icon

Parallax Volatility Advisers’s Gyre Therapeutics GYRE Stock Holding History

Parallax Volatility Advisers’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,901
Closed -$511K – 2029
2023
Q4 		$511K Buy
19,901
+16,981
+582% +$241K ﹤0.01% 1593
2023
Q3 		$21.1K Sell
2,920
-1,037
-26% -$6.94K ﹤0.01% 2078
2023
Q2 		$20.9K Sell
3,957
-1,284
-24% -$4.6K ﹤0.01% 2138
2023
Q1 		$16.3K Buy
5,241
+2,948
+129% +$11.2K ﹤0.01% 2349
2022
Q4 		$9.07K Buy
+2,293
New +$9.36K ﹤0.01% 2570
2018
Q4 		– Sell
-907
Closed -$73K – 3315
2018
Q3 		$73K Buy
+907
New +$71.9K ﹤0.01% 1766

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Parallax Volatility Advisers's GYRE Position: Q1 2024 in Review

Parallax Volatility Advisers sold out of Gyre Therapeutics (GYRE) in Q1 2024, closing a stake of 19,901 shares — an estimated $511K sold.

Parallax Volatility Advisers first reported a position in GYRE in Q3 2018 and held it in 6 quarters. The position peaked at $511K in Q4 2023. 21 funds tracked by Wall St. Rank hold GYRE as of Q1 2024.

  • Parallax Volatility Advisers reported no remaining Gyre Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Parallax Volatility Advisers sold 19,901 Gyre Therapeutics shares in Q1 2024, an estimated $511K.
  • Parallax Volatility Advisers first reported a position in Gyre Therapeutics in Q3 2018 and held it in 6 quarters.
  • Parallax Volatility Advisers's Gyre Therapeutics position peaked at $511K in Q4 2023.
  • 21 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2024.

Based on Parallax Volatility Advisers's 13F filing for Q1 2024, filed 15 May 2024.